Small cell lung cancer (SCLC) is a high-grade neuroendocrine cancer with no effective targeted therapies. Identifying therapeutic targets in SCLC has been challenging, partly because driver mutations in SCLC are primarily loss of function, involving the tumor suppressor genes RB1 and TP53. While TP53 is highly mutated in many adult solid tumors, the near-universal loss of RB1 (protein pRB) is unique to SCLC. I propose to identify new therapeutic targets in SCLC by investigating epistatic and synthetic lethal interactions with pRB loss, with the former being targets acting downstream of pRB and the latter representing dependencies created specifically by pRB loss. I have employed both of these strategies to identify two novel targets, KDM5A and AURKB, that are required for SCLC proliferation and whose specific function is to regulate neuroendocrine differentiation and chromosomal segregation, respectively.
In Aim 1, I will use biochemical and genetic approaches to determine the specific mechanism by which KDM5A regulates ASCL1, a pulmonary neuroendocrine lineage transcriptional activator that is required for SCLC tumor formation.
In Aim 2, based on my preliminary data from a CRISPR screen, I hypothesize that other regulators of chromosomal segregation are synthetic lethal with RB1 loss. I will use direct fluorescence-based competition assays to validate true synthetic lethal interactions. I will then use time-lapse microscopy to determine the underlying mechanism by which pRB loss exacerbates the mitotic phenotype caused by loss of other chromosomal segregation genes.
In Aim 3, I will ask whether KDM5A is necessary for tumor initiation and/or tumor maintenance in vivo using a novel CRISPR-based genetically-engineered mouse model of SCLC that I developed. I'm a medical oncologist with a research background in cancer biology applying for a K08 award with a long-term goal of becoming a tenure-track independent laboratory investigator. I envision developing an independent research program investigating the mechanisms responsible for SCLC pathogenesis with the ultimate goal of identifying new therapies for SCLC patients. During my proposed K08 research training, I will perform mentored research in the laboratory of Dr. William Kaelin at the Dana-Farber Cancer Institute (DFCI). I plan to spend 90% of my time on research and 10% on patient care seeing thoracic oncology patients. I have organized an outstanding advisory committee to help guide my research and career development with faculty members at DFCI, Harvard Medical School, and MIT that are experts in specific areas of my proposed research including: Dr. Stuart Orkin, Dr. David Pellman, Dr. Tyler Jacks, and Dr. Stephen Blacklow. Dr. Bruce Johnson, a world-renowned lung cancer clinical trialist, will serve as my clinical advisor. This outstanding environment at DFCI supplemented with coursework and conferences will help me achieve my long-term career aspirations.

Public Health Relevance

Small cell lung cancer (SCLC) is characterized by near-universal loss of function mutations in RB1, which is a unique feature of SCLC amongst adult solid tumors. This proposal seeks to identify new therapeutic targets in SCLC that are epistatic or synthetic lethal with RB1 loss. These targets will be tested for their role in tumor initiation and/or tumor maintenance using a novel genetically-engineered mouse model of SCLC developed using CRISPR, which will serve as a paradigm for future preclinical in vivo therapeutic target validation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08CA222657-01
Application #
9432056
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
2017-09-19
Project End
2022-08-31
Budget Start
2017-09-19
Budget End
2018-08-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215